Delays in Tocilizumab Therapy for Patients With Giant Cell Arteritis in the United States
Patients with GCA experienced significant delays in starting TCZ therapy. In addition, patients on Medicare or Medicare Advantage plans had significantly higher out-of-pocket costs compared to other patients. These delays and costs are excessive for a vulnerable population with a potentially disabling disease. Further research is needed to investigate causes of delays, the high cost of medication, and effects on clinical outcomes.
Authors
- Dominique Feterman Jimenez (ORCID: https://orcid.org/0000-0001-9861-7997)
- Jenna Thomason (ORCID: https://orcid.org/0000-0002-3942-8982)
- Alison Bays (ORCID: https://orcid.org/0000-0002-7193-6303)
- Jean W. Liew (ORCID: https://orcid.org/0000-0002-8104-2450)
- Grant C. Hughes (ORCID: https://orcid.org/0000-0003-1856-2493)
- Sancia Ferguson (ORCID: https://orcid.org/0000-0002-5702-8659)
Institutions
- Boston University (US)
- University of Wisconsin–Madison (US)
- University of Washington (US)
- University of Maryland, College Park (US)
Publication Details
- Journal
- The Journal of Rheumatology
- Published
- 2025-03-15
- DOI
- https://doi.org/10.3899/jrheum.2024-0988
- Citations
- 1
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 1.52